Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy

Read full text
Authors: Christoffer Rasmus Vissing, A A R Axelsson Raja, Adam S. Helms, S Saberi, Anjali T. Owens, Joseph W. Rossano, Dominic J. Abrams, Jodie Ingles, Belinda Gray, Rachel Lampert, John C. Stendahl, Neal K. Lakdawala
+10 more J. Anthony Ware, Victoria N. Parikh, M Michels, Lia Crotti, Thomas D. Ryan, Iacopo Olivotto, Sharlene M. Day, H Bundgaard, Brian L. Claggett, Carolyn Y. Ho
Cited by: 5
References: 23

Abstract

BACKGROUND: Sarcomere gene variants are a key cause of hypertrophic cardiomyopathy (HCM), and have been associated with worse prognosis. However, it is unclear how comorbidities influence clinical trajectories, the timing of events, and causes of death in sarcomeric and nonsarcomeric HCM. METHODS: We conducted a multicenter longitudinal cohort study of genotyped patients with HCM in the Sarcomeric Human Cardiomyopathy registry (SHaRe). Patients were classified as sarcomeric HCM (pathogenic/likely pathogenic sarcomere variant) or nonsarcomeric HCM (genetically elusive). The influence of genetic classification and comorbidities on the sequence of cardiovascular events were assessed in time-varying Cox proportional hazards models. RESULTS: Among 6120 patients (40% women; 87% probands; 50% sarcomeric HCM), followed for a median of 5.3 years, sarcomeric HCM (n=3082) was associated with a younger age at diagnosis (median 38.1 versus 54.3 years; P

Fields of Study & Subjects

Cardiomyopathy and Myosin Studies Cardiovascular Function and Risk Factors Cardiac electrophysiology and arrhythmias

Publication details

Journal / source
Circulation
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
153
Issue
15
Pages
1104–1116
Publication date
9 March 2026
Language
EN